A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data by Haines, Patrick et al.
Copyright © 2013-2015 A2 Publications
Journal of  Health Economics and Outcomes Research
A Criterion-based Approach for the Systematic and 
Transparent Extrapolation of  Clinical Trial Survival Data
Gabriel Tremblay1, Patrick Haines2*, Andrew Briggs3
Abstract 
Background: Trial data often does not cover a sufficiently long period of  time to truly capture time-to-
event endpoints, however, Health Technology Assessment (HTA) bodies often require overall survival 
(OS) and progression-free survival (PFS) estimates. Often, significant survival effects are found beyond the 
time period observed in clinical trials, thus, extrapolation of  trial results is required for health economic 
and HTA evaluations.
Objectives: This paper looks at different techniques that can be used to extrapolate trial data, as well as 
criteria that should be used to select the most appropriate technique. Using these insights a formal decision-
making criteria will be established, allowing users to follow a systematic approach to extrapolating survival 
estimates. The techniques are then applied to a metastatic breast cancer (MBC) example.
Methods: A criterion-based guide was devised to allow the accurate extrapolation and justification of  
survival estimates in a MBC study comparing eribulin (Halaven) monotherapy with treatment of  their 
(patient’s) physician’s choice (TPC). Parametric and piecewise models are used to extrapolate survival 
estimates, and statistical as well as visual tests are used to decide the most appropriate modelling technique.
Results: In the case study presented, the optimal model was identified as the Accelerated Failure Time 
(AFT) Parametric model using a Gamma distribution with a treatment covariate for OS, and the Kaplan-
Meier survival estimates for PFS.
Conclusions: Survival estimates must be extrapolated to a time point such that the benefits of  a therapy 
can be clearly demonstrated. A systematic approach combined with a formal decision-making structure 
should be used to minimize the potential for bias as well as making the process transparent.
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1. Background
There is a growing need to extrapolate survival curves when the trial data prior to cut-off  does not provide 
enough information on overall survival (OS) and progression free survival (PFS).1 Health Technology 
Assessment (HTA) bodies require manufacturers of  new health technologies to demonstrate the value of  
the product in terms of  OS and PFS gain.2 As a significant portion of  the clinical value is reflected in the 
tail2 of  the survival curve, it is important to understand the different extrapolation techniques in order to 
ensure that the value of  a new intervention can be appropriately presented. 
The primary objective of  this analysis is to compare extrapolation techniques by assessing the incremental 
difference between treatment arms. In addition, this analysis will determine the appropriate technique to 
be used in breast cancer to estimate OS and PFS for the dataset used. The mean incremental difference is 
used in this study because total cost or total survival can be computed from the mean3, and because extreme 
values can be accounted for (unlike when using the median or other statistics).4,5,6
Literature Review for Extrapolation of  Survival in Economic mModels
Clinical trials can be limited in the data they provide as a result of  time and/or budget constraints.  Specifically, 
many trial results are published before the endpoint of  interest (such as OS) is reached for all participants.7 
This can cause a “tip of  the iceberg” effect where a significant proportion of  the benefit is hidden after the 
trial end. In these cases, extrapolation of  the available evidence is necessary to completely measure survival. 
Bias in the endpoint related to the effect of  the assessment schedule is also a potential justification for 
extrapolation.8 This bias is related to the data collection process and creates a stair-step look in the survival 
or PFS curves as the data is not collected continuously.
Traditionally, extrapolation involves the use of  parametric models based on the regression analysis of  
patient-level data using either the exponential, Weibull, Log-normal, Log-logistic, Gamma or Gompertz 
distributions. Other model classes, such as piecewise models which are more flexible than traditional 
parametric models, are rarely used even if  they can offer robust results in some cases.1 
The difference between the two arms in the trial is often based on a treatment covariate. Some argue that 
both the shape and scale of  the extrapolated function has to be modelled with precision, which suggests 
that a treatment covariate would not always be optimal.9  
Different tests can be used to validate the optimal model class as well as the optimal model type or distribution 
within a class. These include visual examination of  the hazard rate and the fit of  the extrapolated survival.10 
The National Institute for Health and Care Excellence Decision Support Unit (NICE DSU) technical 
document explains that many studies do not present a solid case for their model choice. Another criticism 
is that the assumption of  proportional hazards is often used without justification.11 Also, uncertainty in the 
extrapolated estimates is often not modelled.1 
The Case Study
OS was the primary endpoint in a Phase 3 open-label randomized study of  eribulin (Halaven) monotherapy 
versus a treatment of  physician’s choice (TPC) in patients with metastatic breast cancer (Eisai Metastatic 
Breast Cancer Study Assessing Physician’s Choice versus Eribulin [EMBRACE] trial).  In this study, women 
with locally recurrent or metastatic breast cancer were randomly given eribulin mesilate or TPC. The study
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is registered at ClinicalTrials.gov, #NCT00388726.12 The study met its primary objective, showing a 
significant increase in OS for eribulin patients compared to TPC patients. Median overall survival was 13.1 
months (11.8-14.3) in patients receiving eribulin and 10.6 months (95% confidence interval [CI] 9.3-12.5) in 
patients receiving TPC. These results also showed a significant increase in OS for eribulin compared to TPC 
patients, with a median OS of  13.2 months (95% CI 12.1-14.4) versus 10.5 months (9.2-12.0) with TPC. 
2. Methodology
General Approach and Decision-making Criteria
The general approach described and used in this study was inspired by the NICE DSU Technical Report.2 
When there is an extrapolation need there are three steps to the approach, detailed in Appendix A. 
The first step is the initial selection of  the survival model before extrapolation has taken place. This tends 
to involve plotting the log-cumulative hazard of  all treatment options and then using visual inspection 
to determine the appropriate model. The second step involves extrapolating survival results by using the 
appropriate model. In this stage, survival estimates are extrapolated to the end of  the time horizon of  
interest for complete parametric models. Finally, the third step is to use statistical measures and decision 
criteria to select the model that most accurately models survival. Such criteria should not be seen as the 
answer to which model is most appropriate; instead they should be used to guide decisions. 
The Model Classes
In this analysis, three model classes are discussed. The first model class, the proportional hazards (PH) 
model, is relevant when the treatment effect is proportional over time. If  this is true, the log-cumulative 
hazard plots of  two (or more) arms will be parallel.2  To model this hazard rate relation to time we include 
a treatment arm covariate which creates a “pattern” of  hazard difference between each treatment, assuming 
that the hazard differential is constant over time. This is because the PH condition states that covariates are 
multiplicatively related to hazard. This class of  model suggests a stable difference between each treatment 
arm.
In this first model class, we only considered (1) PH parametric models with a treatment covariate. Such 
survival modelling consists of  fitting a distribution to the data, with the most common distributions in 
survival analysis including the Weibull, Exponential and Gompertz distributions.  
Many economic analyses use a PH model to generate the marginal difference between treatment curves by 
applying a hazard ratio of  treatment difference to the control arm of  the trial.11 
Model type (1) will be applied using three PH distributional forms; Weibull, Exponential and Gompertz. 
The Weibull distribution is monotonically increasing, decreasing or constant over time. 
The next model class is recommended when log-cumulative hazard plots are not parallel, but relatively 
straight. For this model class this study focuses on (2) Accelerated Failure Time (AFT) models with a 
treatment covariate and (3) individual parametric models without a treatment covariate.  Unlike PH models, 
AFT models assume that the effect of  a covariate is to accelerate (or decelerate) the hazard by a constant, 
acting like a time-scaling factor.13 Individual models are parametric models that do not use a treatment 
covariate, meaning the extrapolation for each arm is estimated separately. Individual models will also fit a 
single model type to the whole time frame of  interest. Individual models are less flexible than piecewise 
models (discussed later), as the equation must fit the whole pre- and post-trial cut-off  periods, but they 
avoid problems that can arise when transitioning between the pre- and post-trial cut-off. 
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With the previous models, survival estimates were extrapolated from the same analysis for both arms using a 
“treatment effect” covariate to generate the survival difference. With individual models each treatment arm 
will have survival results extrapolated on its own basis, allowing different distributions to be applied to each 
arm. Individual models can result in survival estimates for different treatment arms crossing. Sometimes, 
it is not clinically or statistically appropriate that this happens. However, because the shape and slope are 
determined by the pre cut-off  trial data2 the parametric extrapolation in the post cut-off  period can lead 
to unrealistic cross-over. In other cases, the cross-over can be very important (for example, if  cross-over 
occurs before the trial cut-off  individual’s models should be used).
The final class discussed in this study includes piecewise and other flexible models. Such models are flexible 
enough to perform extrapolation when hazard rates are not constant over time, are monotonic or are 
non-monotonic.2 Piecewise models are often amendments or hybrids, composed of  one or more forms 
of  survival modelling, including Kaplan-Meier survivor functions or parametric extrapolation. In 2011, 
only 2% of  economic models used to estimate mean survival in NICE Technology Appraisals included 
piecewise survival extrapolation.2 Piecewise modelling is recommended in the NICE DSU Technical 
Support Document on extrapolation when log-cumulative hazard plots lines are not straight. Non-straight 
lines mean that the hazard rate is time-dependent, and as such the proportional hazard assumption is not 
respected. This can be confirmed through the use of  a global proportional hazard test. 
Because piecewise modelling uses different extrapolation techniques at different time points, this kind of  
modelling could be less effective at extrapolating beyond the observed data.2 In fact, piecewise survival 
mapping is often dynamic/non-constant or split into extrapolated sections separated by knots, which 
reduce its effectiveness at forecasting the survival with a proper tail, even if  it can be effective at fitting 
the best curve to the observed data.2 In this study, two techniques of  this model class were examined. The 
first technique involves attaching parametric extrapolation survival estimates to the observed Kaplan-Meier 
curve.14 The second technique used was the Royston & Parmar spline technique.15
The first model type tested in this class is (4) Kaplan-Meier survival function with an extrapolated tail. In 
this method, the observed data until trial cut-off  (the first 34 months in the case study) are used to plot the 
Kaplan-Meier survival function. The first 34 months are therefore not extrapolated and the limitations of  
the Kaplan-Meier Survivor function remain valid. The data is then extrapolated past month 34, creating a 
‘tail’ to the survival curve which is attached to the end of  the Kaplan-Meier survival function. The tail is 
forecast using parametric models whilst assuming that the cut-off  (in this example month 34) is in fact the 
first time period (month 0). Therefore, month 35 (cut-off  + 1) is modelled assuming that it is month 1. To 
do this, the survivor function at month 34 is assumed to be at 100%. As an example, if  20% of  the patients 
are still alive at month 34, and the parametric function indicates that the survival should be 100% at time 
0 and 90% at time 1, the extrapolation of  survival will be 18% (20% X 90%) at time “trial cut-off  + 1”, 
or the 35th month. The extrapolated hazard rate could be constant or not, but also monotonic and could 
potentially lead to a change in hazard at the transition between the Kaplan-Meier curve and the extrapolated 
tail (between month 34 and 35). This puts emphasis on the marginal gain prior to extrapolation, which 
decreases the risk of  exaggerating the extrapolated tail benefit.2
The second type of  model tested within this class are (5) Royston and Parmar flexible models.15 Royston 
and Parmar developed flexible parametric models, also called spline-based models, where the extrapolation 
is adjusted to have a different shape between a number of  knots.16 The number of  knots, which define the 
boundary of  the extrapolated section, can vary, but it is recommended to use six or less, creating seven 
areas. Adding knots impacts the degree of  freedom and a large number of  knots potentially adds more 
uncertainty than benefit.16 
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The classic method is to place the knots at predefined percentiles depending on the number of  knots, 
with the distance between each knot being identical.17 A second method would be to run 100 random knot 
placements and select the placements that give the lowest deviance (best Akaike information criterion [AIC], 
Bayesian information criterion [BIC]). As the selection is random, there is no guarantee that the random 
placement selected is the “best” one, so we decided to use a Durrleman & Simon approach (the classic 
method). To select the optimal number of  knots, an AIC/BIC comparison was used as in the Royston 
paper.16 Two types of  models can be used within the Royston & Parmar framework; the PH model using a 
Weibull distribution and the proportional odd (PO) model, using a log-logistic distribution.15  
Decision Criteria
 
This section establishes decision criteria for selecting the optimal model for use in extrapolating outcomes.
First, analyzing the data using statistical tests and visual inspection is necessary to understand the dataset 
and help guide modelers toward the best-fitting model. These occur before extrapolation has taken place.
Criterion 1 – Proportional Hazard Assumption Testing: The PH assumption has to be strongly 
supported by the log-cumulative hazard plots and the PH global statistics if  the selected model advocates 
this assumption.11,2,18
Most published work on survival extrapolation does not use the log-cumulative hazard plots to evaluate the 
PH assumption2, even though it is an important decision-making criteria for the best-fitting model11 and is 
recommended in the NICE DSU technical report. First, if  the log-cumulative hazard line is not straight then 
the hazard is not constant. Secondly, if  the log-cumulative hazard plots of  two treatment arms are parallel, 
then the hazard rate in both arms have a similar relationship to time. These two tests help to identify which 
class of  model is preferable. The log cumulative hazard lines of  the arms may cross, suggesting that one 
arm has an acceleration of  the hazard rate at some point and giving a converging (or diverging) effect on 
the survival functions. In this case the use of  a treatment effect covariate, which assumes a stable relative 
difference, will cause an extrapolation bias. 
This study added a systematic process to assess the PH assumption, using a statistical test in addition to 
visual examination. We used the PH global test, which can be used to evaluate the goodness of  fit of  the data 
using the Schoenfeld residuals.18 This method can be considered more objective than a plot comparison by 
visual inspection, which does not follow a systematic approach.18 A significant result for this test indicates 
a deviation from the PH assumption. 
Once the tests of  criterion 1 are performed, the results of  the extrapolation can be compared, and criteria 
2 to 5 allow us to select the best model.
Criterion 2 – Extrapolated Hazard Function fitting in Time and between Trial Arms: The hazard 
rates have a similar time relation pattern between the extrapolation function and the Kaplan-Meier survivor 
function. The characteristic of  the relation between the hazard rate of  both arms are replicated by the 
modelling technique selected e.g. crossing lines would suggest an individual parametric model. 
Visual examination is one of  the most common “fitting” comparison methods in survival extrapolation.2 
Two types of  visual examination should be performed to ensure proper fitting. First, the fitting of  the 
extrapolated hazard curve to the Kaplan-Meier hazard curve must be examined. This allows the modeler to 
see if  a characteristic of  the curve is not represented in the distributional form used, and guides towards the 
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most accurate model if  so. The second method of  visual inspection involves identifying if  the relationship 
between the extrapolated hazard function within the treatment arms fit well with the hazard relationship 
examined in criterion 1. Models where the hazard patterns seem to fit should be prioritized.
Criterion 3 – Minimal AIC and BIC: For parametric models, the selected model must have a low AIC/
BIC to demonstrate its goodness-of-fit to the survival curve in the pre-extrapolation period.   
AIC and BIC are fitting statistics that are often used to compare parametric models. They are a measure of  
the relative quality of  the statistical model, but models are rarely exclusively selected based on this method.11 
Nevertheless, this technique represents an effective way to evaluate the general fitting of  the model based 
on the data available, but should be used in combination with other selection criteria. The tests from 
criterion 1 to 3 have one major flaw:  As these tests focus on the comparison of  the pre-extrapolation data, 
they do not test the post-extrapolation period.2 The post-extrapolation period could affect the estimated 
survival results and cause significant bias. Therefore, other comparison methods are needed. In this analysis, 
we included two additional methods, which are described in criterion 4 and 5.
Criterion 4 – Uncertainty in the Results: Uncertainty should be accounted for when selecting the best 
model, as a high uncertainty would be a sign of  low robustness.
To assess uncertainty, the CIs surrounding the marginal difference in survival between the treatment arms 
are used. Uncertainty can be measured using a bootstrap method to evaluate the CIs of  the estimates.8   
The nature of  the different extrapolation techniques can have an impact on the estimates. Nevertheless, 
experts should be careful in selecting models with wide CIs.
Criterion 5 – Similitude of  Pre-extrapolation Marginal Gain and Realism of  the Extrapolated 
Marginal Gain: The realism of  the marginal gain should be accounted for when selecting the best model 
as an unrealistic marginal gain would create bias in the economic analysis.
Criterion 5 is the simple comparison of  the pre and post extrapolation area under the curve. In the best-case 
scenario, the pre-extrapolation result has a strong AIC/BIC fit, and for the post-extrapolation period the 
marginal gain should not overestimate the difference between the curves. An inflated difference between 
the two arms caused by an erroneous extrapolation could create a bias in the analysis.
To evaluate the realism of  the post-extrapolation survival gain, we used a ‘rule-of-thumb’, stating that the 
ratio of  the marginal relative difference in the extrapolated period (post cut-off) divided by the number of  
months post-cut-off  should not be higher than the ratio of  marginal difference on the number of  months 
in the pre-extrapolation period. In other words, the average “rate of  survival gain” per month between 
treatments should be equal or inferior in the post-extrapolation period compared to the pre-extrapolation 
period. This simple calculation provides a maximum realistic gap between the two arms, but it should only 
be used as a rule-of-thumb. As an example, if  the marginal difference in the pre-extrapolation period is two 
months over a 34 months period, the “rate of  survival gain” is 0.0588 of  marginal gain per month. If  we 
assume that the result of  the extrapolation over 60 months is 3 months difference between treatments, then 
1 month gain is generated over the last 26 months, which gives a “rate of  survival gain” of  0.0384. The 
rate is smaller than the pre-extrapolation “rate of  survival gain,” and therefore satisfies the rule of  thumb. 
Another characteristic that should be looked at is the realism of  the total marginal gain. If  the total marginal 
gain is lower than the pre-extrapolation marginal gain, it should be explained in detail using the hazard trend 
or by showing a crossing point in the survival data. 
Journal of  Health Economics and Outcomes Research
Copyright © 2013-2015 A2 Publicationswww.jheor.org 153JHEOR 2015;2(2):147-60
Tremblay G, et al.
3. Metastatic Breast Cancer Case Study
At the last trial observation, 22.65% of  patients in the eribulin arm remained alive, compared to 18.47% for 
the TPC arm. The primary reason for justifying extrapolation is a lack of  trial data for a sufficiently long 
period that is able to highlight marginal gains in overall survival. Because the uncertainty in survival increases 
as we move to the right of  a Kaplan-Meier curve, it is sometimes suggested that the last observations be 
removed as they can significantly affect the results of  extrapolation, however the NICE DSU does not 
recommend this.2 In this case study, the data analysis stopped at the trial cut-off, resulting in the exclusion 
of  one patient. The survival curve quickly loses its precision after the trial cut-off  date and sharply falls to 
4.49% when the last uncensored eribulin patient dies, even if  22.65% of  eribulin patients were still alive 
at the end of  the trial. The actual difference between the survival rates in the trial was at 4.2% in favor of  
eribulin, and the survival results at the trial cut-off  was respectively at 13.5% and 6.4% for eribulin and TPC, 
which seemed more realistic for the extrapolation. As the curves are not crossing in the actual data, such 
crossing generated by one patient would generate a bias when extrapolating using the piecewise models 
attached at the tail of  the Kaplan-Meier survivor function (See Appendix B).
With regard to PFS, all patients had reached progression at month 16 in the eribulin group and at month 
18 in the TPC group. As such, there is no need for extrapolation post-cut-off  in this case as each individual 
reached the endpoint within the observed trial period. In this case, the Kaplan-Meier survival function 
proved to be the optimal function to measure PFS in an economic analysis (see Appendix B).
The log-cumulative hazard plots were then analyzed to detect the hazard patterns and identify the optimal 
model class (Figure 1). For OS, the lines are relatively straight, and relatively parallel. However, the hazard 
plots for both treatment arms cross, diverge, and then converge again, meaning the validity of  all models 
should be checked using the other decision making criteria. The global proportional hazard test based on 
residuals does not show a significant result (p-value=0.0845), which indicates that the curves do not deviate 
from the PH assumption, but the p-value is far from convincing enough to justify using the PH assumption 
with no other justification.
Figure 1. Log-cumulative Hazard Plots of  Overall Survival and Progression-free Survival of  Eribulin 
Mesylate and TPC
TPC: treatment of  physicians choice
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Comparison of  Approach
Table 1 presents the OS results for all the extrapolation techniques examined in our general approach, along 
with statistics related to our criterion based approach.
Selection based on Decision Criteria
Criterion 1 – PH Assumption Testing: The PH assumption appears to be a fair assumption for overall 
survival, as tested by visual inspection and the global statistics. Regardless, the crossing of  both lines and an 
apparent convergence could affect the hazard results. 
As the PH assumption seems appropriate, the PH and accelerated failure time models can be used. As the 
visual analysis highlighted some potential problems with hazard rate plots, it is important to also consider the 
other model classes and types. The PH model with treatment covariates and AFT/individual models were 
the optimal model class.  The next step is to evaluate the modeling techniques by comparing extrapolation 
results:
When plots are parallel:
1) PH Parametric Model with Treatment Covariate: The Weibull distribution gives similar hazard 
patterns to the Kaplan-Meier function. In this analysis, a treatment covariate was included, which 
ensures a rational relationship between the hazards of  each arm (Criteria 2). The AIC/BIC evaluation 
indicated that the Weibull distribution is the best fit (Criterion 3). The level of  uncertainty is quite high, 
but the lower CI does not cross 0 (Criterion 4). Criterion 5 was tested using two “rates of  survival gain” 
to compare to the post-extrapolation rate. The first one was the Kaplan-Meier rate, which was of  0.0581 
per month, and the second was the pre-extrapolation “rate of  survival gain” of  the extrapolation results. 
Criterion 5 was satisfied in both cases with an average of  0.016 month (Criterion 5). Furthermore, the 
post-extrapolation period respects the thumb rule and seems conservative (Criterion 5).  Results suggest 
that the Weibull distribution is the best fit for the PH models. 
When plots are not parallel:
2)   Accelerated Failure Time with Treatment Covariates: Both the Log-logistic distribution and the 
Gamma distribution have similar hazard patterns to that of  the Kaplan-Meier function and are based 
on a treatment covariate model, which ensures a rational relationship between the hazard plots of  
each arm (Criteria 2) (Figure 2 presents an example of  the log-cumulative hazard plots for Halaven 
of  the extrapolated function to evaluate criterion 2 for the complete parametric models). The level of  
uncertainty is lower than in the PH models (Criterion 4), and the log-logistic and Gamma distributions 
have the best AIC/BIC profile (Criterion 3). The extrapolation realism thumb rule was satisfied with an 
average of  0.026 month (Criterion 5). The post extrapolation period respects the thumb rule and seems 
conservative (Criterion 5). The results suggest that the best model here uses the Gamma distribution 
followed by the Log-Logistic, but the Gamma has a more conservative marginal gain, and long tails are 
not to be expected for metastatic breast cancer - as such, we would recommend the Gamma distribution. 
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Table 1.  Overall Survival Extrapolation Results
Model 
Type
Area between the Curves Fitting Statistics
Techniques
Sub-
technique
OS Pre 
Cut-off
OS Post 
Cut-off  
Extrapolated 
Tale
Total 
Difference 
in OS
Lower 
Bound 
CI
Higher 
Bound 
CI
Fitting 
Statistics 
(AIC/BIC)
Plots are 
Parallel
(1) PH Parametric 
models with 
treatment covariate
Weibull 1.66 0.36 2.03 0.14 3.98 1947 / 1961
Exponential 1.70 0.71 2.41 0.33 5.11 2008 / 2017
Gompertz 1.63 0.24 1.87 0.10 3.53 1980 / 1994
Plots are 
not 
Parallel
(2) AFT Parametric 
models with 
treatment covariates
Log-Normal 2.22 0.80 3.02 1.26 6.57 1953 / 1967
Log-Logistic 2.20 0.68 2.88 1.34 7.11 1936 / 1950
Gamma 2.00 0.58 2.57 0.57 4.97 1936 / 1955
(3) Individual 
parametric models
Weibull 1.76 0.07 1.83 -0.26 3.93 1946 / 1962
Log-Normal 1.89 0.39 2.28 -1.41 5.96 1954 / 1969
Log-Logistic 1.88 0.22 2.10 -2.82 7.03 1936 / 1952
Exponential 1.70 0.71 2.41 -0.67 5.48 2008 / 2016
Gamma 1.79 -0.11 1.68 -2.13 5.49 1937 / 1960
Gompertz 2.62 -0.05 2.57 0.68 4.47 1980 / 1996
Plots 
are not 
Straight 
Lines: 
Consider 
Piecewise 
Models
(4) SF + parametric 
tale extrapolation
Weibull 1.98 1.06 3.04 2.74 3.39 1947/ 1961*
Log-Normal 1.98 1.09 3.07 2.86 3.32 1953/ 1967*
Log-Logistic 1.98 1.09 3.07 2.92 3.39 1936/ 1950*
Exponential 1.98 1.02 3.00 2.75 3.29 2008/ 2017*
Gamma 1.98 1.08 3.05 2.77 3.39 1936/ 1955*
Gompertz 1.98 1.05 3.03 2.74 3.36 1980/ 1994*
(5) Royston & 
Parmar flexible 
models
Weibull PH 
with 1 node 1.78 -0.07 1.72 0.15 3.52 0 / 0
Log-Logistic 
PO with 1 
node 1.77 -0.02 1.75 0.17 3.55 0 / 0
OS: overall survivial; CI: confidence interval; AIC: Akaike information criterion; BIC: Bayesian information criterion; PH: 
proportional hazard; AFT: accelerated failure time; SF: survival function; PO: proportional odd (model) 
3) Complete Parametric Extrapolation of  the Individual Model: The Log-logistic, Gamma 
and Weibull distribution have similar hazard patterns to the Kaplan-Meier estimator (Criteria 2). A 
converging hazard rate is realistic given the data, but crossing of  the survival estimates is present for 
some of  the distributions, which is not reflected in the data and would create a bias in the results 
(criterion 5). The level of  uncertainty appears very high, with the lower bound of  the CI crossing 0 
for all extrapolations (Criteria 4). The AIC/BIC evaluation indicated that the Log-logistic and Gamma 
distributions provide the best fit (Criterion 3). The extrapolation realism thumb rule was satisfied with 
an average of  0.007 month (Criterion 5). The post-extrapolation period respects the thumb rule and 
seems very conservative, except for the Gamma distribution, which is negative. This negative effect can 
be caused by the convergence of  the hazard rate at the end of  the pre-extrapolation period, but the 
survival curve should cross post-extrapolation (Criterion 5). Therefore, the Log-logistic distribution 
should be used for this model type. 
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Figure 2. Log-cumulative Plots of  the Extrapolated Function for Halaven for the Complete Parametric 
Models
When Plots are not straight lines:
4) Survival Function + Parametric Tail Extrapolation: Log-logistic, Gamma, and also Weibull 
distributions have similar hazard patterns to the Kaplan-Meier estimator and are based on a treatment 
covariate model, which ensure a rational relationship between the hazard of  each arms (Criteria 2). The 
AIC/BIC indicate that the Log-logistic, Gamma and Weibull distributions provide the best fit (Criterion 
3). Assuming no uncertainty in the Kaplan-Meier portion of  the curve, the level of  uncertainty in the 
extrapolated section is limited (Criterion 4). The thumb rule was satisfied with an average of  0.040 
month (Criterion 5). All extrapolations are close to the thumb rule threshold (Criterion 5). The Gamma 
distribution displays the best fitting profile in this extrapolation class.
5) Royston and Parmar Flexible Models: The PO and PH models offer very similar results and hazard 
patterns to the Kaplan-Meier function (Criterion 2). Both models have a good AIC/BIC profile 
(Criterion 3).  The level of  uncertainty is similar to the PH models with covariates, and the CIs do not 
cross 0 (Criteria 4). The extrapolation realism thumb rule was satisfied with an average of  -0.001 month 
(Criterion 5). Both models project a negative post-extrapolation difference, which is not suggested by 
the data (Criterion 5). Due to the crossing problem, we would not recommend using these extrapolation 
techniques in this context. The results show that for a PH model, one knot should be used (lowest AIC 
and BIC), results are displayed in Appendix C. For the PO model, no knots should be used, which is 
equivalent to using an individual parametric model.
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Selecting the Optional Model for Overall Survival
In the optimal model class (the PH model class where plots are parallel), the Weibull model with use of  
a treatment covariate is the superior model. In the individual and AFT model class (where plots are not 
parallel), the Gamma AFT model with use of  a treatment covariate is superior. In the Piecewise model class 
(plots are not straight lines), the Gamma tail attached to the survival function is the superior model. Among 
all classes, we would recommend the use of  a Gamma AFT model with a treatment covariate because it 
has a better AIC/BIC profile, less uncertainty and a strong realism of  the pre- and post-extrapolation area 
under the curve. Appendix D presents the model comparison based on our criteria.
4. Discussion and Conclusion
The comparison of  the different classes of  models allows us to discuss the limitations and advantages of  
each type of  model. The case study used enables us to highlight some concerns about different types of  
methodology, but similar studies should be performed using this technique.
Below are some key pieces of  information discussed through this study:
• Kaplan-Meier survivor functions can be widely affected by the last observation, and do not offer any 
form of  extrapolation beyond the last observation. 
• Visual examination is important, but statistical tests and technical decision criteria are needed.
• PH parametric models are inherently coherent with the need to evaluate a difference between the arms 
survival curves. Validating the PH assumption is critical to the use of  these models. 
• Individual and AFT models can offer a good alternative to PH models when the PH assumption is 
not validated. 
• More flexible models, such as piecewise models, can offer a robust alternative to PH/AFT or individual 
models when hazard rates do not follow clear patterns. 
• Analysts looking to extrapolate survival data should compare models following a clear process, and not 
restrict themselves to simpler models.
In the case study presented, the optimal model was identified as the AFT Parametric model using a Gamma 
distribution with a treatment covariate for overall survival, and the Kaplan-Meier estimator for PFS. 
Having a strong decision-making process is important and can avoid generating bias. Selecting a method 
that is conservative and in line with the criteria should be a priority, rather than presenting the method that 
provided the highest marginal benefit. 
Finally, the optimal model should be included in economic analysis or HTA analysis under the base case 
scenario, but the second best model should be included in the sensitivity analysis. 
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Appendix A
PH: proportional hazard; AFT: accelerated failure time; SF: survival function
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Appendix B
Appendix C
 Proportional Hazard Proportional Odd
Knots AIC BIC AIC BIC
0 1946.4 1961.9 1936.4 1951.8
1 1937.2 1960.4 1938.2 1961.4
2 1940.2 1971.1 1940.8 1971.7
3 1943.8 1982.4 1944.8 1983.5
4 1946.9 1993.3 1948.2 1994.6
AIC: Akaike information criterion; BIC: Bayesian information criterion
Appendix D
Criteria Recommendation
Model Types 1 2 3 4 5
(1) PH Parametric models with treatment covariate √ √ √ √ ! Weibull
(2) AFT Parametric models with treatment 
covariates √ √ √ √ !
Gamma
(3) AFT individual parametric model √ ! √ ! ! Log-logistic
(4) SF + parametric tale extrapolation NA √ √ √ √ Gamma
(5) Royston & Parmar flexible models √ √ √ √ 1 knot
PH: proportional hazard; AFT: accelerated failure time;  SF: survival function
